Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.39
(1.56%)
SEK 0.39
(1.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 23.95 Million SEK | -4.0% |
| 2022 | 24.95 Million SEK | 105.54% |
| 2021 | 12.14 Million SEK | -18.98% |
| 2020 | 14.98 Million SEK | 118.06% |
| 2019 | 6.87 Million SEK | 12.29% |
| 2018 | 6.11 Million SEK | 118.75% |
| 2017 | 2.79 Million SEK | 128.59% |
| 2016 | 1.22 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.81 Million SEK | -41.97% |
| 2024 Q2 | 3.7 Million SEK | -12.14% |
| 2023 FY | 24 Million SEK | -3.81% |
| 2023 Q3 | 6.86 Million SEK | -0.15% |
| 2023 Q1 | 3.76 Million SEK | -21.02% |
| 2023 Q2 | 6.87 Million SEK | 82.4% |
| 2023 Q4 | 6.57 Million SEK | -4.21% |
| 2022 FY | 24.95 Million SEK | 105.54% |
| 2022 Q3 | 6.06 Million SEK | -8.4% |
| 2022 Q2 | 6.62 Million SEK | -11.73% |
| 2022 Q1 | 7.5 Million SEK | 63.61% |
| 2022 Q4 | 4.76 Million SEK | -21.35% |
| 2021 Q1 | 2.12 Million SEK | 118.19% |
| 2021 FY | 12.14 Million SEK | -18.98% |
| 2021 Q3 | 3.04 Million SEK | 27.95% |
| 2021 Q2 | 2.38 Million SEK | 12.19% |
| 2021 Q4 | 4.58 Million SEK | 50.35% |
| 2020 Q1 | 5.04 Million SEK | 63.2% |
| 2020 Q2 | 6.32 Million SEK | 25.38% |
| 2020 Q4 | 973.45 Thousand SEK | -63.18% |
| 2020 FY | 14.98 Million SEK | 118.06% |
| 2020 Q3 | 2.64 Million SEK | -58.18% |
| 2019 Q2 | 1.21 Million SEK | -33.38% |
| 2019 Q1 | 1.82 Million SEK | 98.09% |
| 2019 Q4 | 3.09 Million SEK | 314.8% |
| 2019 FY | 6.87 Million SEK | 12.29% |
| 2019 Q3 | 745 Thousand SEK | -38.63% |
| 2018 Q4 | 920 Thousand SEK | 0.0% |
| 2018 FY | 6.11 Million SEK | 118.75% |
| 2017 FY | 2.79 Million SEK | 128.59% |
| 2016 FY | 1.22 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 92.2% |
| Ziccum AB (publ) | 27.87 Million SEK | 14.075% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -46.054% |
| BioArctic AB (publ) | 89.62 Million SEK | 73.273% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 43.812% |
| Mendus AB (publ) | 129.13 Million SEK | 81.45% |
| Genovis AB (publ.) | 88.19 Million SEK | 72.84% |
| Intervacc AB (publ) | 79.78 Million SEK | 69.976% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -35.465% |
| Active Biotech AB (publ) | 44.8 Million SEK | 46.541% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 82.375% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 71.198% |
| Aptahem AB (publ) | 10.01 Million SEK | -139.233% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 92.549% |
| Kancera AB (publ) | 63.07 Million SEK | 62.024% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 82.216% |
| Fluicell AB (publ) | 28.61 Million SEK | 16.294% |
| Saniona AB (publ) | 1.07 Million SEK | -2124.166% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -230.222% |
| Biovica International AB (publ) | 133.72 Million SEK | 82.087% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -21.042% |
| AcouSort AB (publ) | 25.87 Million SEK | 7.427% |
| Xintela AB (publ) | 57.31 Million SEK | 58.207% |
| Abliva AB (publ) | 27.86 Million SEK | 14.038% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 87.621% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -334.033% |
| OncoZenge AB (publ) | 15.9 Million SEK | -50.608% |
| Amniotics AB (publ) | 29.07 Million SEK | 17.604% |
| 2cureX AB (publ) | 36.51 Million SEK | 34.404% |
| CombiGene AB (publ) | 44.14 Million SEK | 45.736% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -63.477% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.418% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.739% |
| Corline Biomedical AB | 30.16 Million SEK | 20.597% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 58.722% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -229.585% |
| I-Tech AB | 40.14 Million SEK | 40.335% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 97.213% |
| Cyxone AB (publ) | 28.21 Million SEK | 15.098% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 78.098% |
| Biosergen AB | 26.8 Million SEK | 10.648% |
| Cantargia AB (publ) | 290.01 Million SEK | 91.74% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4258.59% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 86.819% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 15.435% |
| Nanologica AB (publ) | 69.88 Million SEK | 65.724% |
| SynAct Pharma AB | 224.49 Million SEK | 89.33% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 45.775% |
| LIDDS AB (publ) | 27.75 Million SEK | 13.685% |
| Lipum AB (publ) | 37.3 Million SEK | 35.791% |
| BioInvent International AB (publ) | 441.4 Million SEK | 94.573% |
| Alzinova AB (publ) | 36.39 Million SEK | 34.184% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 91.733% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -204.906% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 79.183% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -9.405% |
| Simris Alg AB (publ) | 38.64 Million SEK | 38.01% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 83.247% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 93.302% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 78.403% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -62.954% |